Dulaglutide, semaglutide, and tirzepatide exhibit comparable gastrointestinal adverse event risk
1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in…
Eli Lilly, Tan France launch Zepbound ‘Changing the Thread’
New innovative campaign weaves science and storytelling to help reframe obesity as a chronic disease INDIANAPOLIS, Nov. 10,…
Mounjaro mounts to top spot in Indian drug market; Oct sales touch ₹100 cr, ETPharma
New Delhi: Maintaining its growth momentum for the seventh straight month, Eli Lilly’s type-2 diabetes and weight-loss drug…
Walmart making it easier to get super-popular weight loss drug Zepbound for 50% off
A new partnership between Walmart and drug maker Eli Lily will make it easier for people to access…
Popular Weight Loss Drugs Like Ozempic May Cause Major Muscle Loss Without Boosting Fitness, Study Warns
A woman injects herself with a GLP-1 receptor antagonist drug. (© Mauricio – stock.adobe.com) GLP-1 drugs like semaglutide…